Introduction
The development of ligand-targeted therapeutics in anticancer therapy has gained momentum in recent years (1) . Systemic cytotoxic chemotherapy shows little selectivity and side effects. One strategy to improve the lack of selectivity is to couple therapeutics to antibodies or smaller molecule peptides (2) . Among the most relevant peptide receptors, the bombesin receptors are of major interest, because they were found to be overexpressed in various cancers such as prostate (3, 4) , breast (5, 6) , and small cell lung cancer (7) . The human counterparts of bombesin, namely gastrin-releasing peptide (8, 9) and neuromedin B (8) , have been found in mammalian tissue. Gastrin-releasing peptide receptors (GRPR) are overexpressed on a variety of human tumors such as prostate, breast, and lung cancer. Bombesin (BBN) is a 14 amino acid peptide with high affinity for these GRPRs. Bombesin and gastrin-releasing peptide (GRP) are potent neuropeptides expressed by prostate cancer neuroendocrine cells and are related to the progression of this malignancy.
Nanoliposomes are double-membrane lipid vesicles capable of packaging drugs for various delivery applications (10) . Nanopegylated liposomes can evade the reticuloendothelial system and remain in the circulation for prolonged periods, improving tumor targeting and efficacy in animal models (11, 12) . Nano-pegylated liposomes provide passive targeting because nanoliposome accumulation in tumors is by means of the enhanced permeability and retention (EPR) effect through leaky tumor vasculature (12) . Preclinical studies have shown that cytotoxic agents entrapped in pegylated liposomes tend to accumulate in tumors (13, 14) .
Preclinical studies of tumor therapy with radionuclideliposome conjugates or liposome-mediated radiotherapeutics have been reported (15) (16) (17) (18) . Rhenium-188 is a radionuclide used for imaging and therapeutic dual applications due to its short physical half-life of 16.9 h with 155 keV gamma emissions for imaging, and its 2.12 MeV β emission with maximum tissue penetration range of 11 mm for tumor therapeutics (19) . In addition, 188 Re can be obtained from a commercial nuclear generator, which makes it convenient for routine research and clinical use.
Chemoradiotherapy is a standard treatment for patients with locally advanced rectal cancer. Direc targeted therapy approaches target tumor antigens to change signalling by monoclonal antibodies, peptide or small molecule drugs. Drugs can actively target tumors using tumor-specific antibody or peptide ligands binding to receptors that are present on tumor cells. In this study, a new combination of peptide targeted radiochemo-therapeutics was designed and studied for treating solid tumors of the pancreas by intravenous administration. The in vivo nuclear images of tumor, prolonged survival time and therapeutic efficacy of radiochemotherapeutics of 188 Re-(DXR)-liposome-BBN were evaluated in AR42J malignant pancreas solid tumor-bearing mice. 188 Re as sodium perrhenate (NaReO 4 ). The pegylated liposome (Nano-X) was provided by Taiwan Liposome Co. (Taipei, Taiwan). N,N-bis(2-mercaptoethyl)-N' ,N'-diethylethylenediamine (BMEDA) were purchased from ABX (Radeberg, Germany). Stannous chloride (SnCl 2 ) was purchased from Merck (Darmstadt, Germany). Glucoheptonate powder and doxorubicin was purchased from Sigma-Aldrich Corp. (Bangalore, India). Sepharose CL-6B column were purchased from GE Healthcare (Uppsala, Sweden). All other chemicals were purchased from Merck. Dulbecco's modified Eagle's medium (DMEM) cell culture medium and fetal bovine serum (FBS) was purchased from Gibco (USA).
Cell cultures and animal model. The AR42J human pancreas carcinoma cell line was obtained from the American Type Culture Collection (Manassas, VA, USA). It was grown in Dulbecco's modified Eagle's medium (DMEM) medium supplemented with 10% (v/v) fetal bovine serum (FBS) and 2 mM L-glutamine at 37˚C in 5% CO 2 . Cells were detached with 0.05% trypsin/0.53 mM EDTA in Hanks' balanced salt solution (HBSS). Four-week-old male nude mice were obtained from the National Animal Center of Taiwan (Taipei, Taiwan), with food and water being provided ad libitum in the animal house of the INER. Animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at the Institute of Nuclear Energy Research. Mice were subcutaneously inoculated with 2x10 6 tumor cells in the right hind flank. Ten days after inoculation, the animals developed tumors of ~50-100 mm 3 in size. 188 Re-(DXR)-liposome-BBN. The method for radiolabeling BMEDA with 188 Re was as previously described (15, 16) . The labeling efficiency of the 188 Re-BMEDA complexes was checked by paper chromatography with normal saline as the eluent.
Preparation of

188
Re-BMEDA was encapsulated in the liposomes using the ammonium sulfate gradient loading procedure, the labeling processes of 188 Re-(DXR)-liposome-BBN were as follows. The pegylated nanoliposomes (0.5 ml), DSPE-PEG-BBN (5 µl; 40 mg/ml)with or without DXR (80 µl; 140 mg/ml) had added high specific activity 188 Re-BMEDA (450-650 MBq per 0.5 ml) solution and incubation at 60˚C for 30 min. The 188 Re-liposome-BBN or 188 Re-DXR-liposome-BBN was separated from free 188 Re-BMEDA using sepharose CL-6B column (GE Healthcare) eluted with normal saline. The labeling efficiency of the pegylated nanoliposomes was determined using the activity in pegylated nanoliposomes or liposome-DXR-BBN after separation divided by the total activity before separation. The amount of doxorubicin trapped inside the liposome was analyzed.
Calculation of the amount of bombesin molecules on the surface of liposomes. The amount of bombesin on liposome solution was determined by BCA assay (bombesin molecules/ml liposome). The particle size and the number of phospholipid molecules per liposome can be measured by particle analyzer and phosphate assay separately. The amount of particle per ml liposome solution can be calculated through the concentration of phospholipid and particle size of liposome (vesicles/ml liposome). Finally, the amount of bombesin molecules per vesicle through the amount of bombesin on liposome solution (bombesin molecules/ml liposome) and the amount of particle per ml liposome solution were calculated. In this experiment, the average amount of bombesin molecules on the surface of liposome is 511. 188 Re-liposome-BBN. Imaging was acquired using low-energy, high-resolution collimators at 1, 24, 48 and 72 h after intravenous injection of 188 Re-liposome-BBN with or without cold BBN (2 mg/mouse). For imaging acquisition, the mice were anesthetized with 1-2% isoflurane in 100% O 2 . The energy window was set at 155 keV ± 10-15%, the FOV (field of view) was 12.5 cm. SPECT imaging was followed by CT image acquisition (X-ray source: 50 kV, 0.4 mA; 256 projections) with the animal in exactly the same position. Images were calibrated to standardized uptake values (SUV) (15, 20) . For calculating standardised tumor uptake value (SUV), known radio activity Re-188 was performenced as reference. The SUV was determined from the regions of interest (ROI) on the tumor with uptake. The SUV was calculated according to the following standard formula: measured activity concentration (µCi/g)/[injected dose (µCi)/body weight (g)]. The images revealed a high uptake in tumors at 1 and 24 h after intravenous injection.
MicroSPECT imaging and semi-quantification analysis of targeted
Therapeutic efficacy studies. Nude mice were used and each was subcutaneously inoculated with AR42J cells (2x10 6 ) in the right hind flank. Approximately 10 days after inoculation, tumor-bearing mice were divided randomly into groups, 8-10 mice per group. The study was divided in two experiments: (A) combinational radio-chemotherapeutic efficacy of Re and average 3.7 µmol phospholipids), Lipo-Dox-BBN (2 mg/kg DXR and average 3.7 µmol phospholipids) and normal saline by single i.v. injection, respectively. Treatments were initiated when the volume of tumors was ~50-100 mm 3 . The treatments were performed on day 0 as a single dose. Tumor was measured twice weekly by a digital calipers to document tumor growth. Tumor measurements were converted into tumor volume (V) using the formula (21, 22) : V = (Y x W 2 )/2; where Y and W are the larger and smaller perpendicular diameters, respectively. All data are expressed as mean ± standard deviation. The mean tumor growth inhibition rate (MGI) was calculated according to the volume of the tumor (23): growth rate of the treated group/ growth rate of untreated group. Following standard animal-use protocols, termination was mandated on reaching one or both of the following criteria: a tumor weight of >2 g (2 ml volume) or total body weight loss of >20% (24) . The combination therapeutic enhancement results were evaluated by the combination index (CI) (23, 25) . The CI expected growth inhibition rate/ observed growth inhibition rate. The expected growth rate of combination treatment = tumor growth inhibition rate of drug A only x tumor growth inhibition rate of drug B only. In this study, drug A is 188 Re-DXR-liposome-BBN, and drug B is lipo-Dox-BBN. An index >1 points to the synergistic effect, while that of <1 indicates less than an additive effect.
Results
Labeling efficiency of 188 Re-(DXR)-liposome-BBN. The encapsulation efficiency of 188
Re-BMEDA in pegylated liposome-BBN and liposome-BBN contain DXR was 54 and 76%, respectively. The radiochemical purity of 188 Re-(DXR)-liposome-BBN was >95%. The average particle size of 188 Re-(DXR)-liposome (~90 nm) was similar to the particle sizes before 188 Re-BMEDA encapsulation.
MicroSPECT/CT imaging of 188 Re-liposome-BBN. To confirm the specific targeting of the tumor sites of passive 188 Re-liposome-BBN, microSPECT/CT imaging was performed. The microSPECT/CT imaging showed accumulated 188 Re-liposome-BBN in the liver, spleen and tumor (Fig. 1A) . The microSPECT/CT imaging of 188 Re-liposome-BBN pointed to significant target and uptake in the tumors until 48 h after intravenous injection. The SUV of 188 Re-liposome-BBN in tumor reach the peak at 24 h after injection (2.13±0.98) ( Table I) . Contrary to microSPECT/CT imaging of 188 Re-liposome-BBN with cold BBN (2 mg/mouse), the microSPECT/CT imaging showed significant decrease of 188 Re-liposome-BBN uptake in the tumors at 24 h after injection (Fig. 1B) . In study (A), the survival curves for the different treatment groups are compared in Fig. 2B Table II .
In study (B), the survival curves for the different treatment groups are compared in Fig. 3B Re-(DXR)-liposome-BBN in AR42J tumor-bearing mouse model. Table III .
Tumor growth inhibition Survival --------------------------------------------------------------------------------------------------------------------------------------------------------------------
Discussion
The nuclear molecular imaging such as single photon emission computer tomography (SPECT) are valuable tools for new anticancer drug discovery and development in preclinical animal models of human disease. In our previous studies, the results of biodistribution, pharmacokinetics and micro-SPECT/CT imaging demonstrated the benefits of passive radio-therapeutics of 188 Re-liposome in C26 colon carcinoma ascities, C26 colon solid tumor and HT-29 colon solid tumor animal models (15, 16, 20, 26) . In this study, the tumor targeting and therapeutic efficacy of bimodality radiochemo-combination treatment of 188 Re-(DXR)-liposome-BBN was investigated. The in vivo Re-DXR-liposome-BBN. P-value for comparisons of survival curves of various treatment groups are listed in Table III.   Table III . The therapeutic efficacy of dose-dependent effect of radio-chemo therapeutic efficacy of 188 Re-(DXR)-liposome-BBN in AR42J tumor-bearing mouse model. microSPECT/CT imaging result of Fig. 1 (30, 31) . In this study, we use radiochemo-therapeutic 188 Re-DXR-liposome-BBN for drug delivery to improve therapeutic efficacy and to reduce toxicity. In therapeutic experiment (A) and (B), the results (Table II) show dose-dependent anti-tumor activity of 188 Re. The results (Table III) Table III. Many effects have been demonstrated by conjugating various targeting ligands to the liposome surface to increase specificity of interaction of liposomal drugs with targeted cells and to enhance the amount of drugs delivered into tumor cells. Antibodies, peptides, growth factors and folate can selectively bind to target antigens or receptors overexpressed on the tumor cell. RGD-modified liposomes (32) (33) (34) , integrin-targeted paclitaxel nanoparticles (35) (36) (37) (38) , and folate-conjugated liposomes (39) have been demonstrated to increase the intracellular delivery and therapeutic efficacy of chemotherapeutic agents in vivo. In our study, BBN targeted peptide conjugated with radio-chemotherapeutics 188 Re-(DXR)-liposome was designed for treating solid pancreatic tumors by intravenous administration.
Tumor growth inhibition
Apoptosis occurs spontaneously and is enhanced by irradiation. Radiation-induced apoptosis has been observed in vivo (40, 41) . Radiation-induced apoptosis is considered to be one of the main cell death mechanisms following exposure to irradiation. Apoptosis plays a modest role in the treatment response of most solid tumors, which constitute the main human malignancies. This is observed in vivo such as intestinal crypt, salivary and lacrimal glands with non-dividing cells, lymphocytes that are non-dividing, and is frequently seen early within 4-6 h after irradiation (40, 42, 43) . 188 Re kills tumor cells through a cross-fire or non-specific cell killing effect. Li et al have studied the therapeutic efficacy of radioimmunotherapy (RIT) of 188 Re-labeled herceptin, the tumor inhibition rate (IR) was 48.8±4.9 after the 4th week of 188 Re-herceptin (11.1 MBq) administration by intravenous injection (29) . Radiochemotherapeutics of 188 Re-DXR-liposome attained significant survival time, ascites inhibition (decreased by 49 and 91% at 4 days after treatment; P<0.05) and tumor inhibition in mice (15, 44) . Radiotherapeutics with 188 Re-liposomes provided better survival time (increased by 34.6% of life span; P<0.05), tumor and ascites inhibition (decreased by 63.4 and 83.3% at 7 days after treatment; P<0.05) in mice compared with chemotherapeutics of 5-fluorouracil (5-FU) (45) . In conclusion, we used peptide targeted radiochemo-therapeutic multifunctional nanoliposome as carrier for drug delivery to improve therapeutic efficacy. The inhibition of tumor growth in mice treated with 188 Re-DXR-liposome-BBN was precisely controlled and had longer survival time than those treated with anti-cancer drug, 188 Re-liposome-BBN (MGI = 0.130; 75%), Lipo-Dox-BBN (MGI = 0.666; 3.61%) and untreated control mice. The additive tumor regression effect (Table II) was observed (CI 0.946) for co-delivery radiochemo-therapeutics of 188 Re-DXR-liposome-BBN.
